Last reviewed · How we verify
Solid tumor and CT DNA
Solid tumor and CT DNA is a Biologic drug developed by Gustave Roussy, Cancer Campus, Grand Paris. It is currently in Phase 1 development.
Here's a 2-sentence factual summary of Solid tumor and CT DNA: Solid tumors are a type of cancer studied in various clinical trials, including those for Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, and Unresectable Malignant Solid Neoplasm. Computed Tomography (CT) is an intervention used in some of these trials, but the modality of CT DNA is unknown.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Solid tumor and CT DNA |
|---|---|
| Sponsor | Gustave Roussy, Cancer Campus, Grand Paris |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations (PHASE2)
- Testing the Combination of Two Anti-cancer Drugs, Peposertib (M3814) and Tuvusertib (M1774) for Advanced Solid Tumors (PHASE1)
- MoleculAr Profiling for Pediatric and Young Adult Cancer Treatment Stratification 2 (NA)
- M7824 and Topotecan or Temozolomide in Relapsed Small Cell Lung Cancers (PHASE1, PHASE2)
- TRC102 and Temozolomide for Relapsed Solid Tumors and Lymphomas (PHASE1, PHASE2)
- Hypoxia-driven Prostate Cancer Genomics (HYPROGEN)
- Immunization Strategy With Intra-tumoral Injections of Pexa-Vec With Ipilimumab in Metastatic / Advanced Solid Tumors. (PHASE1)
- Evaluation of Clinical, Radiomics and Molecular Features of Lung Metastasis in PDAC Patients (LUMACA Trial)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Solid tumor and CT DNA CI brief — competitive landscape report
- Solid tumor and CT DNA updates RSS · CI watch RSS
- Gustave Roussy, Cancer Campus, Grand Paris portfolio CI
Frequently asked questions about Solid tumor and CT DNA
What is Solid tumor and CT DNA?
Who makes Solid tumor and CT DNA?
What development phase is Solid tumor and CT DNA in?
Related
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing